Xinjiang Bai Hua Cun Pharma Tech Co.,Ltd Logo

Xinjiang Bai Hua Cun Pharma Tech Co.,Ltd

600721.SS

(1.0)
Stock Price

7,08 CNY

2.11% ROA

3.15% ROE

131.83x PER

Market Cap.

3.013.924.770,00 CNY

0.07% DER

0% Yield

5.7% NPM

Xinjiang Bai Hua Cun Pharma Tech Co.,Ltd Stock Analysis

Xinjiang Bai Hua Cun Pharma Tech Co.,Ltd Fundamental Analysis

Fundamental analysis in stock investing is like studying the foundation of a house before buying it. It involves looking at a company's financial health, like its earnings, assets, and debts, to determine if it's a good investment based on its fundamental strength and potential for growth.

Xinjiang Bai Hua Cun Pharma Tech Co.,Ltd Fundamental Stock Analysis
# Analysis Rating
1 DER

The stock has a low debt to equity ratio (0%), which means it has a small amount of debt compared to the ownership it holds

2 Assets Growth

Company's revenue has experienced consistent growth over the last three years, indicating a favorable financial trajectory and making it an attractive investment choice.

3 Buffet Intrinsic Value

The company's stock seems undervalued (279) by Warren Buffett's formula, indicating a promising investment opportunity as its intrinsic value exceeds the market price.

4 ROE

The stock's ROE indicates a negative return (-4.09%) on shareholders' equity, suggesting poor financial performance.

5 ROA

The stock's ROA (-2.75%) indicates that it's not effectively utilizing its assets to generate profits, making it a less favorable option to invest and earn consistent returns.

6 PBV

The stock's elevated P/BV ratio (4.48x) raises concerns about its overvaluation, making it an imprudent choice for investors seeking value.

7 Revenue Growth

Company's revenue has remained stagnant over the past three years, indicating a lack of growth and making it a less favorable option.

8 Net Profit Growth

Throughout the last five years, this company's net profit has remained unchanged, indicating a lack of growth and making it a less favorable investment option.

9 Graham Number

The company's Graham number indicates that it is overvalued compared to its stock price, suggesting a potentially unfavorable investment opportunity.

10 Dividend Growth

The company's dividend growth has remained unchanged for three years, signaling a lack of positive momentum and making it a less favorable investment choice.

11 Dividend

The company has not distributed any dividends in the past three years, which may raise concerns for investors looking for regular income from their investments.

Xinjiang Bai Hua Cun Pharma Tech Co.,Ltd Technical Analysis

Technical analysis in stock investing is like reading the patterns on a weather map to predict future weather conditions. It involves studying past stock price movements and trading volumes to make predictions about where a stock's price might go next, without necessarily looking at the company's financial health.

Xinjiang Bai Hua Cun Pharma Tech Co.,Ltd Technical Stock Analysis
# Analysis Recommendation
1 Awesome Oscillator Sell
2 MACD Buy
3 RSI Hold
4 Stoch RSI Hold

Xinjiang Bai Hua Cun Pharma Tech Co.,Ltd Price Chart

Financial Statements

Financial statements are like report cards for companies. They show how much money a company makes (income statement), what it owns and owes (balance sheet), and where it spends its money (cash flow statement), helping stock investors understand if a company is healthy and worth investing in.

Income Statements

An income statement for a company is like a scoreboard for its profits and losses. It shows how much money the company made (revenue) and how much it spent to make that money (expenses), helping stock investors see if a company is making a profit or not.

Revenue in stock investing is the total amount of money a company earns from its sales, and it's a key factor that investors consider to assess a company's financial performance and growth potential.

Xinjiang Bai Hua Cun Pharma Tech Co.,Ltd Revenue
Year Revenue Growth
1993 4.991.000
1994 86.856.319 94.25%
1995 139.264.275 37.63%
1996 215.220.512 35.29%
1997 145.413.591 -48.01%
1998 114.839.513 -26.62%
1999 107.054.344 -7.27%
2000 92.621.676 -15.58%
2001 39.080.183 -137%
2002 225.726.218 82.69%
2003 340.636.029 33.73%
2004 119.277.368 -185.58%
2005 46.175.166 -158.31%
2006 52.846.488 12.62%
2007 37.562.320 -40.69%
2008 39.089.941 3.91%
2009 63.649.936 38.59%
2010 696.564.251 90.86%
2011 1.209.836.888 42.42%
2012 1.118.869.820 -8.13%
2013 1.181.709.696 5.32%
2014 1.108.870.132 -6.57%
2015 808.805.222 -37.1%
2016 744.574.204 -8.63%
2017 419.502.543 -77.49%
2018 419.189.442 -0.07%
2019 262.017.718 -59.99%
2020 84.530.414 -209.97%
2021 281.353.040 69.96%
2022 349.884.562 19.59%
2023 393.999.757 11.2%
2023 369.277.391 -6.69%
2024 416.103.548 11.25%

Research and Development Expenses are the costs a company incurs to create and improve its products or services, which can be important for investors to evaluate a company's innovation and potential for future growth.

Xinjiang Bai Hua Cun Pharma Tech Co.,Ltd Research and Development Expenses
Year Research and Development Expenses Growth
1993 0
1994 0 0%
1995 0 0%
1996 0 0%
1997 0 0%
1998 0 0%
1999 0 0%
2000 0 0%
2001 0 0%
2002 0 0%
2003 0 0%
2004 0 0%
2005 0 0%
2006 0 0%
2007 0 0%
2008 0 0%
2009 0 0%
2010 0 0%
2011 0 0%
2012 0 0%
2013 0 0%
2014 0 0%
2015 0 0%
2016 20.466.727 100%
2017 0 0%
2018 0 0%
2019 0 0%
2020 6.114.512 100%
2021 5.251.125 -16.44%
2022 27.482.350 80.89%
2023 34.432.244 20.18%
2023 31.869.198 -8.04%
2024 31.783.828 -0.27%

General and Administrative Expenses are the costs a company incurs to run its day-to-day operations, such as office rent, salaries, and utilities, which investors consider to understand a company's overall efficiency and management effectiveness.

Xinjiang Bai Hua Cun Pharma Tech Co.,Ltd General and Administrative Expenses
Year General and Administrative Expenses Growth
1993 312.000
1994 2.474.508 87.39%
1995 8.415.310 70.6%
1996 6.819.205 -23.41%
1997 10.328.307 33.98%
1998 15.890.246 35%
1999 24.564.354 35.31%
2000 51.539.491 52.34%
2001 12.787.446 -303.05%
2002 35.037.583 63.5%
2003 29.710.725 -17.93%
2004 41.585.547 28.56%
2005 33.420.458 -24.43%
2006 20.151.509 -65.85%
2007 13.548.469 -48.74%
2008 15.331.307 11.63%
2009 14.675.658 -4.47%
2010 28.445.431 48.41%
2011 52.104.588 45.41%
2012 62.133.554 16.14%
2013 41.048.788 -51.37%
2014 70.895.055 42.1%
2015 63.819.068 -11.09%
2016 49.249.977 -29.58%
2017 15.767.139 -212.36%
2018 19.283.642 18.24%
2019 19.812.033 2.67%
2020 18.583.101 -6.61%
2021 17.063.647 -8.9%
2022 17.192.437 0.75%
2023 160.733.428 89.3%
2023 14.434.044 -1013.57%
2024 39.573.804 63.53%

EBITDA stands for Earnings Before Interest, Taxes, Depreciation, and Amortization. It is a measure that helps stock investors analyze a company's profitability by looking at its earnings without considering certain expenses. This helps to get a clearer picture of the company's financial performance and its ability to generate cash flow.

Xinjiang Bai Hua Cun Pharma Tech Co.,Ltd EBITDA
Year EBITDA Growth
1993 1.193.000
1994 9.820.618 87.85%
1995 23.993.778 59.07%
1996 23.833.775 -0.67%
1997 9.407.084 -153.36%
1998 -666.875 1510.62%
1999 -21.034.926 96.83%
2000 -63.264.417 66.75%
2001 26.119.773 342.21%
2002 33.963.871 23.1%
2003 67.660.578 49.8%
2004 16.953.902 -299.09%
2005 -129.517.731 113.09%
2006 12.933.422 1101.42%
2007 18.392.644 29.68%
2008 14.317.890 -28.46%
2009 22.399.822 36.08%
2010 259.080.328 91.35%
2011 396.180.038 34.61%
2012 387.661.625 -2.2%
2013 401.960.056 3.56%
2014 10.700.365 -3656.51%
2015 -46.503.154 123.01%
2016 326.313.159 114.25%
2017 91.261.899 -257.56%
2018 164.014.685 44.36%
2019 111.854.485 -46.63%
2020 -132.772.291 184.25%
2021 107.431.022 223.59%
2022 55.654.796 -93.03%
2023 191.127.122 70.88%
2023 93.872.674 -103.6%
2024 22.708.720 -313.38%

Gross profit is the money a company makes from selling its products or services after subtracting the cost of producing or providing them, and it is an important measure for investors to understand a company's profitability.

Xinjiang Bai Hua Cun Pharma Tech Co.,Ltd Gross Profit
Year Gross Profit Growth
1993 3.246.000
1994 16.503.271 80.33%
1995 38.598.559 57.24%
1996 41.411.006 6.79%
1997 42.794.299 3.23%
1998 35.819.983 -19.47%
1999 19.082.043 -87.72%
2000 21.594.880 11.64%
2001 14.515.972 -48.77%
2002 44.998.334 67.74%
2003 66.145.323 31.97%
2004 36.824.894 -79.62%
2005 26.065.226 -41.28%
2006 24.209.314 -7.67%
2007 25.179.646 3.85%
2008 27.610.875 8.81%
2009 27.051.594 -2.07%
2010 305.359.287 91.14%
2011 521.178.673 41.41%
2012 392.500.341 -32.78%
2013 315.016.543 -24.6%
2014 48.455.782 -550.11%
2015 -63.670.629 176.1%
2016 33.690.698 288.99%
2017 120.208.378 71.97%
2018 188.225.308 36.14%
2019 127.044.636 -48.16%
2020 -136.900.483 192.8%
2021 112.650.248 221.53%
2022 139.665.564 19.34%
2023 199.602.035 30.03%
2023 181.083.942 -10.23%
2024 173.418.992 -4.42%

Net income in stock investing is like the money a company actually gets to keep as profit after paying all its bills, and it's an important measure to understand how well a company is doing financially.

Xinjiang Bai Hua Cun Pharma Tech Co.,Ltd Net Profit
Year Net Profit Growth
1993 1.198.000
1994 6.995.923 82.88%
1995 12.643.985 44.67%
1996 18.244.326 30.7%
1997 14.952.965 -22.01%
1998 -19.987.162 174.81%
1999 -39.835.271 49.83%
2000 -87.194.059 54.31%
2001 4.703.593 1953.78%
2002 3.437.946 -36.81%
2003 16.403.027 79.04%
2004 -8.915.283 283.99%
2005 -121.119.681 92.64%
2006 1.283.028 9540.14%
2007 5.630.531 77.21%
2008 6.703.014 16%
2009 17.060.947 60.71%
2010 41.038.765 58.43%
2011 75.539.094 45.67%
2012 20.465.356 -269.11%
2013 2.991.697 -584.07%
2014 -233.625.372 101.28%
2015 -405.982.726 42.45%
2016 139.134.157 391.79%
2017 -564.115.293 124.66%
2018 -807.864.682 30.17%
2019 34.384.702 2449.49%
2020 -319.764.475 110.75%
2021 59.827.132 634.48%
2022 -34.727.505 272.28%
2023 18.768.921 285.03%
2023 12.972.337 -44.68%
2024 7.990.104 -62.36%

EPS, or earnings per share, is a measure that shows how much profit a company has earned for each outstanding share of its stock, and it is important for stock investors as it helps understand the profitability of a company and compare it with other companies in the market.

Xinjiang Bai Hua Cun Pharma Tech Co.,Ltd Earning per Share (EPS)
Year Earning per Share (EPS) Growth
1993 0
1994 0 0%
1995 0 0%
1996 0 0%
1997 0 0%
1998 0 0%
1999 0 0%
2000 -1 0%
2001 0 0%
2002 0 0%
2003 0 0%
2004 0 0%
2005 -1 100%
2006 0 0%
2007 0 0%
2008 0 0%
2009 0 0%
2010 0 0%
2011 0 0%
2012 0 0%
2013 0 0%
2014 -1 0%
2015 -2 100%
2016 0 0%
2017 -1 100%
2018 -2 50%
2019 0 0%
2020 -1 0%
2021 0 0%
2022 0 0%
2023 0 0%
2023 0 0%
2024 0 0%

Cashflow Statements

Cashflow statements show the movement of money in and out of a company, helping stock investors understand how much money a company makes and spends. By examining cashflow statements, investors can assess if a company is generating enough cash to pay its bills, invest in growth, and provide returns to stockholders.

Free cash flow is the leftover cash that a company generates after covering its operating expenses and capital expenditures, which is important for stock investors as it shows how much money a company has available to invest in growth, pay dividends, or reduce debt.

Xinjiang Bai Hua Cun Pharma Tech Co.,Ltd Free Cashflow
Year Free Cashflow Growth
1998 -64.402.139
1999 -1.570.242 -4001.41%
2000 -8.287.942 81.05%
2001 -19.955.380 58.47%
2002 -42.526.464 53.08%
2003 -74.095.386 42.61%
2004 93.588.242 179.17%
2005 7.208.473 -1198.31%
2006 6.205.277 -16.17%
2007 -13.534.507 145.85%
2008 -49.957.216 72.91%
2009 -130.791.500 61.8%
2010 -274.745.425 52.4%
2011 92.300.322 397.66%
2012 177.607.327 48.03%
2013 -166.185.143 206.87%
2014 114.855.551 244.69%
2015 342.881.482 66.5%
2016 -146.163.004 334.59%
2017 -104.922.513 -39.31%
2018 24.528.315 527.76%
2019 -32.637.419 175.15%
2020 -27.053.073 -20.64%
2021 28.682.803 194.32%
2022 50.770.398 43.5%
2023 44.840.684 -13.22%
2023 -3.565.658 1357.57%
2024 30.612.984 111.65%

Operating cash flow represents the cash generated or consumed by a company's day-to-day operations, excluding external investing or financing activities, and is crucial for stock investors as it shows how much cash a company is generating from its core business operations.

Xinjiang Bai Hua Cun Pharma Tech Co.,Ltd Operating Cashflow
Year Operating Cashflow Growth
1998 -35.816.464
1999 -443.642 -7973.28%
2000 -3.312.339 86.61%
2001 32.634.627 110.15%
2002 -33.612.244 197.09%
2003 -67.073.428 49.89%
2004 95.661.157 170.12%
2005 8.095.003 -1081.73%
2006 6.480.984 -24.9%
2007 11.085.987 41.54%
2008 12.251.032 9.51%
2009 -3.568.048 443.35%
2010 339.112.920 101.05%
2011 559.640.574 39.41%
2012 342.002.939 -63.64%
2013 6.631.614 -5057.16%
2014 202.160.848 96.72%
2015 423.580.952 52.27%
2016 -108.315.499 491.06%
2017 -50.260.023 -115.51%
2018 80.553.717 162.39%
2019 -6.795.414 1285.41%
2020 -23.281.214 70.81%
2021 34.721.683 167.05%
2022 53.177.027 34.71%
2023 62.079.865 14.34%
2023 0 0%
2024 39.451.162 100%

Capex, short for capital expenditures, refers to the money a company spends on acquiring or upgrading tangible assets like buildings, equipment, or technology, which is important for stock investors as it indicates how much a company is investing in its infrastructure to support future growth and profitability.

Xinjiang Bai Hua Cun Pharma Tech Co.,Ltd Capital Expenditure
Year Capital Expenditure Growth
1998 28.585.675
1999 1.126.600 -2437.34%
2000 4.975.603 77.36%
2001 52.590.007 90.54%
2002 8.914.220 -489.96%
2003 7.021.958 -26.95%
2004 2.072.915 -238.75%
2005 886.530 -133.82%
2006 275.706 -221.55%
2007 24.620.494 98.88%
2008 62.208.248 60.42%
2009 127.223.451 51.1%
2010 613.858.345 79.27%
2011 467.340.251 -31.35%
2012 164.395.611 -184.28%
2013 172.816.757 4.87%
2014 87.305.296 -97.95%
2015 80.699.470 -8.19%
2016 37.847.505 -113.22%
2017 54.662.490 30.76%
2018 56.025.401 2.43%
2019 25.842.004 -116.8%
2020 3.771.860 -585.13%
2021 6.038.879 37.54%
2022 2.406.628 -150.93%
2023 17.239.181 86.04%
2023 3.565.658 -383.48%
2024 8.838.178 59.66%

Balance Sheet

Balance sheets provide a snapshot of a company's financial health and its assets (such as cash, inventory, and property) and liabilities (like debts and obligations) at a specific point in time. For stock investors, balance sheets help assess the company's overall worth and evaluate its ability to meet financial obligations and support future growth.

Equity refers to the ownership interest or stake that shareholders have in a company, representing their claim on its assets and earnings after all debts and liabilities are paid.

Xinjiang Bai Hua Cun Pharma Tech Co.,Ltd Equity
Year Equity Growth
1994 28.905.441
1995 60.822.059 52.48%
1996 195.212.419 68.84%
1997 203.625.572 4.13%
1998 273.242.291 25.48%
1999 221.516.262 -23.35%
2000 130.407.472 -69.86%
2001 122.679.884 -6.3%
2002 178.767.487 31.37%
2003 229.910.771 22.24%
2004 218.653.728 -5.15%
2005 2.587.399 -8350.72%
2006 19.475.849 86.71%
2007 337.410.523 94.23%
2008 344.281.744 2%
2009 361.613.996 4.79%
2010 1.049.049.443 65.53%
2011 1.097.783.290 4.44%
2012 1.104.259.675 0.59%
2013 1.352.102.238 18.33%
2014 997.282.108 -35.58%
2015 455.100.660 -119.13%
2016 2.298.415.090 80.2%
2017 1.733.029.489 -32.62%
2018 919.584.504 -88.46%
2019 954.695.566 3.68%
2020 624.164.886 -52.96%
2021 686.252.061 9.05%
2022 667.023.483 -2.88%
2023 708.846.911 5.9%
2023 706.615.374 -0.32%
2024 732.950.285 3.59%

Assets represent the valuable resources that a company owns, such as cash, inventory, property, and equipment, and understanding a company's assets helps investors assess its value and potential for generating future profits.

Xinjiang Bai Hua Cun Pharma Tech Co.,Ltd Assets
Year Assets Growth
1994 103.256.218
1995 180.458.742 42.78%
1996 465.422.947 61.23%
1997 396.050.957 -17.52%
1998 477.661.549 17.09%
1999 427.514.421 -11.73%
2000 346.922.524 -23.23%
2001 313.186.611 -10.77%
2002 586.304.271 46.58%
2003 753.775.718 22.22%
2004 585.820.461 -28.67%
2005 290.416.280 -101.72%
2006 259.700.216 -11.83%
2007 742.287.882 65.01%
2008 813.096.697 8.71%
2009 957.428.374 15.07%
2010 4.076.558.328 76.51%
2011 4.409.894.344 7.56%
2012 4.418.125.616 0.19%
2013 4.438.680.081 0.46%
2014 4.165.746.970 -6.55%
2015 4.062.986.274 -2.53%
2016 2.783.933.231 -45.94%
2017 2.032.765.005 -36.95%
2018 1.248.330.745 -62.84%
2019 1.291.205.717 3.32%
2020 974.684.317 -32.47%
2021 982.313.014 0.78%
2022 1.001.329.612 1.9%
2023 1.044.336.508 4.12%
2023 1.062.010.154 1.66%
2024 1.112.372.470 4.53%

Liabilities refer to the financial obligations or debts that a company owes to creditors or external parties, and understanding a company's liabilities is important for investors as it helps assess the company's financial risk and ability to meet its obligations.

Xinjiang Bai Hua Cun Pharma Tech Co.,Ltd Liabilities
Year Liabilities Growth
1994 74.350.777
1995 119.636.683 37.85%
1996 270.210.528 55.72%
1997 192.425.385 -40.42%
1998 204.419.258 5.87%
1999 205.998.159 0.77%
2000 216.515.052 4.86%
2001 190.506.725 -13.65%
2002 407.536.784 53.25%
2003 523.864.945 22.21%
2004 367.166.732 -42.68%
2005 287.828.879 -27.56%
2006 240.224.366 -19.82%
2007 404.877.358 40.67%
2008 468.814.952 13.64%
2009 595.814.376 21.32%
2010 3.027.508.884 80.32%
2011 3.312.111.053 8.59%
2012 3.313.865.940 0.05%
2013 3.086.577.843 -7.36%
2014 3.168.464.861 2.58%
2015 3.607.885.613 12.18%
2016 485.518.140 -643.1%
2017 299.735.515 -61.98%
2018 328.746.240 8.82%
2019 336.510.151 2.31%
2020 350.519.430 4%
2021 296.060.953 -18.39%
2022 334.306.129 11.44%
2023 335.489.597 0.35%
2023 355.394.780 5.6%
2024 377.855.265 5.94%

Xinjiang Bai Hua Cun Pharma Tech Co.,Ltd Financial Ratio (TTM)

Valuation Metrics

Revenue per Share
1.05
Net Income per Share
0.06
Price to Earning Ratio
131.83x
Price To Sales Ratio
7.59x
POCF Ratio
26.93
PFCF Ratio
37.97
Price to Book Ratio
4.07
EV to Sales
7.19
EV Over EBITDA
38.75
EV to Operating CashFlow
25.75
EV to FreeCashFlow
35.94
Earnings Yield
0.01
FreeCashFlow Yield
0.03
Market Cap
3,01 Bil.
Enterprise Value
2,85 Bil.
Graham Number
1.62
Graham NetNet
0.23

Income Statement Metrics

Net Income per Share
0.06
Income Quality
4.9
ROE
0.03
Return On Assets
0.02
Return On Capital Employed
0.03
Net Income per EBT
0.87
EBT Per Ebit
1.01
Ebit per Revenue
0.06
Effective Tax Rate
0.15

Margins

Sales, General, & Administrative to Revenue
0.08
Research & Developement to Revenue
0.08
Stock Based Compensation to Revenue
-0
Gross Profit Margin
0.49
Operating Profit Margin
0.06
Pretax Profit Margin
0.07
Net Profit Margin
0.06

Dividends

Dividend Yield
0
Dividend Yield %
0
Payout Ratio
0
Dividend Per Share
0

Operating Metrics

Operating Cashflow per Share
0.29
Free CashFlow per Share
0.21
Capex to Operating CashFlow
0.28
Capex to Revenue
0.08
Capex to Depreciation
1.45
Return on Invested Capital
0.03
Return on Tangible Assets
0.02
Days Sales Outstanding
202.71
Days Payables Outstanding
201.37
Days of Inventory on Hand
227.83
Receivables Turnover
1.8
Payables Turnover
1.81
Inventory Turnover
1.6
Capex per Share
0.08

Balance Sheet

Cash per Share
0,63
Book Value per Share
1,94
Tangible Book Value per Share
1.84
Shareholders Equity per Share
1.94
Interest Debt per Share
0
Debt to Equity
0
Debt to Assets
0
Net Debt to EBITDA
-2.19
Current Ratio
1.81
Tangible Asset Value
0,70 Bil.
Net Current Asset Value
0,22 Bil.
Invested Capital
453566620
Working Capital
0,27 Bil.
Intangibles to Total Assets
0.03
Average Receivables
0,23 Bil.
Average Payables
0,11 Bil.
Average Inventory
129448626
Debt to Market Cap
0

Dividends

Dividends in stock investing are like rewards that companies give to their shareholders. They are a portion of the company's profits distributed to investors, typically in the form of cash payments, as a way for them to share in the company's success.

Xinjiang Bai Hua Cun Pharma Tech Co.,Ltd Dividends
Year Dividends Growth
1997 0

Xinjiang Bai Hua Cun Pharma Tech Co.,Ltd Profile

About Xinjiang Bai Hua Cun Pharma Tech Co.,Ltd

Xinjiang Bai Hua Cun Pharma Tech Co.,Ltd engages in the pharmaceutical research and development, clinical trials, biomedicine, commercial properties, and other businesses. The company was formerly known as Xinjiang Baihuacun Co., Ltd. and changed its name to Xinjiang Bai Hua Cun Pharma Tech Co.,Ltd in July 2021. Xinjiang Bai Hua Cun Pharma Tech Co.,Ltd was founded in 1959 and is headquartered in Urumqi, China.

CEO
Mr. Hui Huang
Employee
759
Address
No. 1, South Alley
Urumqi, 830002

Xinjiang Bai Hua Cun Pharma Tech Co.,Ltd Executives & BODs

Xinjiang Bai Hua Cun Pharma Tech Co.,Ltd Executives & BODs
# Name Age
1 Ms. Ziyun Cai
Chief Financial Officer & Secretary
70
2 Mr. Hui Huang
Rotating GM & Director
70
3 Mr. Zhengtian Lu
Executive Deputy GM & Director
70
4 Mr. Yan Xia
Deputy GM & Director
70

Xinjiang Bai Hua Cun Pharma Tech Co.,Ltd Competitors